[New approaches for the treatment of dyslipidemia]

Abstract

Reduction in the risk of cardiovascular complications through modification of lipids is currently focused on lowering low density lipoproteins-cholesterol, with statins being the preferred drugs. New agents, under research, such as antibodies neutralizing PCSK9, will have a special place for the management of patients with intolerance to statins of severe dyslipemias. Drugs used to modify the concentration of high density lipoproteins-cholesterol and triglycerides have not been accompanied by the expected reductions in the rate of cardiovascular complications.

Keywords: Cholesterol ester transfer protein inhibitors; Estatinas; Hipercolesterolemia; Hipolipidemiantes; Hypercholesterolemia; Hypolipemiant; Inhibidores de la proteína transportadora de ésteres de colesterol; Proprotein convertase subtilisin/kexin type 9; Proproteína convertasa subtilisina/kexina tipo 9; Statins; Tratamiento de la hipercolesterolemia; Treatment of hypercholesterolemia.